(IN BRIEF) A major data-driven study from Aalborg University has found that missing periods of continuous glucose monitor use in people with diabetes are closely linked to poorer blood sugar control â and likely not random. Analyzing sensor data from … Read the full press release
Posted in Business, Denmark, Education, Healthcare, News, Science, Society, Technology
Tagged Aalborg University, blood sugar control, CGM sensors, continuous glucose monitoring, Denmark diabetes statistics, diabetes research, Diabetes Technology & Therapeutics, digital health tools, glycemic regulation, missing data impact, Morten HasselstrĂžm Jensen, New Insights: Gaps in Glucose Monitoring May Mask Treatment Failures in Diabetes Patients, Novo Nordisk, patient engagement, personalized diabetes care, real-world evidence, sensor usage patterns, Simon Lebech Cichosz, Steno Diabetes Center North Jutland, type 1 diabetes, type 2 diabetes
(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least one prior therapy. The approval is based on the … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anti-CD38 antibody, autologous stem cell transplant, bortezomib, CACA, Category I Recommendation, Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology, clinical data, CSCO, dexamethasone, Global Head of Oncology, ICARIA-MM phase 3 study, innovative regulatory pathways, innovative therapies, IsaFiRsT real-world study, Lecheng Pilot Program, lenalidomide, local authorities, medical community, National Medical Products Administration, newly diagnosed multiple myeloma, NMPA, Olivier Nataf, overall response rate, overall survival, Pd, pomalidomide, R/R MM, real-world evidence, regulatory submission, relapsed or refractory multiple myeloma, RWE, Sanofi, Sanofi in China, Sarclisa
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europeâs biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.Â
HOW TO GET STARTED?